ProCE Banner Activity

Immunotherapy in Cancer: Insights for Nurses

Slideset Download
In this downloadable slideset with slide notes from the live meeting series, expert faculty review the use of immunotherapy in cancer, indications and administration of approved immune checkpoint inhibitors, and cases highlighting common clinical scenarios for nurses in the management of immune-related adverse events.

Released: May 05, 2016

Expiration: May 04, 2017

No longer available for credit.

Share

Faculty

Cindi Bedell

Cindi Bedell, RN, MSN, APRN-C

Nurse Practitioner
Texas Oncology
Plano East
Plano, Texas

Grace Cherry

Grace Cherry, RN, MSN, NP

Oncology Nurse Practitioner
UCLA Melanoma Program
Los Angeles, California

Michele S. Barber

Michele S. Barber, MS, NP, AOCNP

Oncology Nurse Practitioner
Department of Hematology/Oncology
Lahey Health Hospital and Medical Center
Peabody, Massachusetts

Diane Cope

Diane Cope, PhD, ARNP-BC, AOCNP

Oncology Nurse Practitioner
Chair,
Clinical Directions Team
Florida Cancer Specialists and Research Institute
Fort Myers, Florida

Gail Kwarciany

Gail Kwarciany, MSN, RN-BC, OCN, AOCNS

Oncology Clinical Nurse Specialist
The University of Texas Medical Branch
Galveston, Texas

Sarah Lowry

Sarah Lowry, MSN, ACNP-BC, AOCNP

Instructor
School of Medicine
Oregon Health & Science University
Oncology and Palliative Care Nurse Practitioner
Community Hematology & Oncology
Portland, Oregon

Jody Pelusi

Jody Pelusi, PhD, FNP, AOCNP

Oncology Nurse Practitioner
Phoenix, Arizona

Jayshree Shah

Jayshree Shah, RN, FPN-C, AOCNP, MSN, BSN, BS

Nurse Practitioner
GI/Thoracic Division
John Theurer Cancer Center
Hackensack University Medical Center
Hackensack, New Jersey

Anne Zobec

Anne Zobec, RN, MS, AOCNP

Oncology Nurse Practitioner
Rocky Mountain Cancer Center
Colorado Springs, Colorado

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Genentech BioOncology

Merck Oncology

Target Audience

This program is intended for oncology nurses and other healthcare professionals who provide care for patients with cancer being treated with immunotherapy.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss with patients the key principles underlying immunotherapy in cancer care
  • Review with patients the available data on different immunotherapies and their clinical implications on current therapy decisions
  • Incorporate guideline and expert recommendations into the management of adverse events associated with the use of immunotherapy for patients with cancer

Program Director Disclosure

Program Director

Cindi Bedell, RN, MSN, APRN-C

Nurse Practitioner
Texas Oncology
Plano East
Plano, Texas

Cindi Bedell, RN, MSN, APRN-C, has disclosed that she has received fees for non-CME/CE services from Amgen, Celgene, and Genentech.

Grace Cherry, RN, MSN, NP

Oncology Nurse Practitioner
UCLA Melanoma Program
Los Angeles, California

Grace Cherry, MSN, NP, has disclosed that she has received consulting fees from Amgen and Merck and fees for non-CME/CE services from Genentech.

Faculty Disclosure

Primary Author

Michele S. Barber, MS, NP, AOCNP

Oncology Nurse Practitioner
Department of Hematology/Oncology
Lahey Health Hospital and Medical Center
Peabody, Massachusetts

Michele S. Barber, MS, NP, AOCNP, has no real or apparent conflicts of interest to report.

Diane Cope, PhD, ARNP-BC, AOCNP

Oncology Nurse Practitioner
Chair,
Clinical Directions Team
Florida Cancer Specialists and Research Institute
Fort Myers, Florida

Diane G. Cope, PhD, ARNP-BC, AOCNP, has no real or apparent conflicts of interest to report.

Gail Kwarciany, MSN, RN-BC, OCN, AOCNS

Oncology Clinical Nurse Specialist
The University of Texas Medical Branch
Galveston, Texas

Gail Kwarciany, MSN, RN-BC, OCN, AOCNS, has no real or apparent conflicts of interest to report.

Sarah Lowry, MSN, ACNP-BC, AOCNP

Instructor
School of Medicine
Oregon Health & Science University
Oncology and Palliative Care Nurse Practitioner
Community Hematology & Oncology
Portland, Oregon

Sarah Lowry, MSN, ACNP-BC, AOCNP, has no real or apparent conflicts of interest to report.

Jody Pelusi, PhD, FNP, AOCNP

Oncology Nurse Practitioner
Phoenix, Arizona

Jody Pelusi, PhD, FNP, AOCNP, has no real or apparent conflicts of interest to report.

Jayshree Shah, RN, FPN-C, AOCNP, MSN, BSN, BS

Nurse Practitioner
GI/Thoracic Division
John Theurer Cancer Center
Hackensack University Medical Center
Hackensack, New Jersey

Jayshree Shah, RN, FPN-C, AOCNP, MSN, BSN, BS, has disclosed that she has received consulting fees from Celgene, Novartis, and Teva, and fees for non-CME/CE services from Boehringer Ingelheim, Celgene, Lilly, Merck, Novartis, and Teva.

Anne Zobec, RN, MS, AOCNP

Oncology Nurse Practitioner
Rocky Mountain Cancer Center
Colorado Springs, Colorado

Anne Zobec, RN, MS, AOCNP, has disclosed that she has received fees for non-CME/CE services from Boehringer Ingelheim, Genentech, and Seattle Genetics.

Staff Disclosure

Staff

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no real or apparent conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Hope Rindal, MS

Editorial Contributor

Hope Rindal, MS, has no real or apparent conflicts of interest to report.

Instructions for Credit

Credit Designation

This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine.


Accreditation Statement

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 05, 2016, through May 04, 2017:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge and competency of oncology nurses to optimally communicate with and care for patients eligible for treatment with immunotherapy.